Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 15,419,354 shares of its common stock at a price to the public of $3.10 per share. The offering is expected to close on or about June 20, 2017 subject to satisfaction of customary closing conditions. Pacific Biosciences also granted the underwriters a 30-day option to purchase up to an additional 2,312,903 shares of its common stock. After deducting the underwriting discount and estimated offering expenses payable by the Company, the Company expects to receive net proceeds of approximately $45.9 million, assuming no exercise of the underwriter’s option to purchase additional shares. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Pacific Biosciences intends to use the net proceeds from the offering for general corporate purposes,
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- PacBio moved to Neutral at JPMorgan after guidance cut [Seeking Alpha]Seeking Alpha
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $2.50 price target on the stock, down previously from $7.00.MarketBeat
PACB
Earnings
- 2/15/24 - Beat
PACB
Sec Filings
- 4/16/24 - Form 8-K
- 4/15/24 - Form PRE
- 4/11/24 - Form POSASR
- PACB's page on the SEC website